{"success":true,"data":{"pressRelease":{"id":"104002","rtpr_id":"nPn892Qrba","ticker":"REGN","exchange":"NASDAQ","all_tickers":["REGN"],"title":"REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026","author":"PR Newswire","published_at":"2026-07-30T15:19:00.063Z","article_body":"REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026\n\nPR Newswire\n\nNEW YORK, July 30, 2026\n\nImportant Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial\nRisk Misrepresentations. The lawsuit alleges Regeneron investors overpaid\nwhile the Company characterized slowing event accrual as potentially\nfavorable, even as the study allegedly faced heightened risk of failing its\nprimary endpoint.\n\nNEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a class action lawsuit has\nbeen filed on behalf of shareholders who purchased securities between August\n1, 2025 and May 15, 2026. Find out if you could qualify to recover your losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4742050-15&h=3135563518&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195030%26wire%3D4&a=Find+out+if+you+could+qualify+to+recover+your+losses)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nRegeneron shares declined approximately 13.95%, or $102.09 per share, from the\nClass Period high through the final disclosure-related decline. Applications\nto serve as lead plaintiff must be filed by September 14, 2026.\n\nThe Alleged Clinical Trial Risk Securities Fraud Methodology\n\nAccording to the lawsuit, Regeneron provided investors with materially\npositive information about the Phase III Fianlimab-Libtayo Study while\nallegedly mischaracterizing the risk created by a prolonged slowdown in\nprogression-free survival event accrual. The complaint alleges that investors\nwere not told that preliminary statistical assumptions were flawed and that\nthe trial was at increased risk of missing statistical significance.\n\nThe lawsuit contends that the Company framed the slowdown as consistent with\ndurable efficacy in the active treatment arms, rather than as a warning sign\nthat the study's statistical design and endpoint assumptions were under\npressure.\n\nHow Event Accrual Allegedly Affected Investor Expectations\n\nThe Phase III Fianlimab-Libtayo Study tested a LAG-3 inhibitor combination as\na first-line treatment for advanced melanoma. The complaint alleges that\nRegeneron's optimistic discussion of delayed event accrual caused investors to\nform expectations about the program that was not supported by the study's\nactual risk profile.\n\n\"This case presents important questions about clinical-trial risk disclosure\nobligations in the biotechnology sector, particularly where investors are told\nthat delayed events may reflect durable treatment activity. The complaint\nalleges that shareholders were not given a fair picture of the study's\nstatistical risks before the program missed its primary endpoint.\" -- Joseph\nE. Levi, Esq.\n\nKey Clinical Trial Risk Allegations for Shareholders\n\n * The complaint alleges that the slowdown in event accrual was presented as\npotentially favorable to the active treatment arms.\n * The lawsuit contends that the Phase III study's preliminary statistical\nassumptions were materially flawed.\n * Plaintiffs allege that the active treatment arms were not demonstrating the\nclinical separation investors were led to expect.\n * The action claims that the study's risk of failing its primary endpoint was\nunderstated during the Class Period.\n * Regeneron later announced that the trial did not reach statistical\nsignificance for improvement in progression-free survival.\nSubmit your information here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4742050-15&h=3035660308&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195030%26wire%3D4&a=Submit+your+information+here)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REGN Lawsuit\n\nQ: What is the REGN class action lawsuit about? A: A securities class action\nhas been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging\nmaterially false and misleading statements between August 1, 2025 and May 15,\n2026. Shares fell approximately 13.95% after the Company disclosed a protocol\nexpansion for progression-free survival analysis and later announced that the\nPhase 3 Fianlimab trial did not reach statistical significance. Investors who\npurchased shares during the Class Period and suffered losses may be eligible\nto seek compensation.\n\nQ: What specific misstatements does the REGN lawsuit allege? A: The complaint\nalleges Regeneron made materially false or misleading statements regarding the\nPhase III Fianlimab-Libtayo Study, including statements that allegedly\nminimized the clinical and statistical risk associated with slowing event\naccrual. When the protocol change and later trial failure were disclosed, the\nstock price declined sharply.\n\nQ: What court was the REGN class action filed in? A: The case was filed in\nthe United States District Court for the Southern District of New York,\ngoverned by the Private Securities Litigation Reform Act of 1995.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What happens after I contact Levi & Korsinsky? A: An attorney will\nreview your trading history at no cost and provide an initial assessment of\nyour potential eligibility.\n\nQ: What if I already sold my REGN shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/regn-deadline-alert-suewallst-reminds-regeneron-pharmaceuticals-regn-investors-of-securities-class-action-deadline-on-september-14-2026-302839146.html\n(https://www.prnewswire.com/news-releases/regn-deadline-alert-suewallst-reminds-regeneron-pharmaceuticals-regn-investors-of-securities-class-action-deadline-on-september-14-2026-302839146.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2803395\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn892Qrba","title":"REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026","author":"PR Newswire","ticker":"REGN","created":"2026-07-30T15:19:00.063Z","tickers":["REGN"],"exchange":"NASDAQ","article_body":"REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026\n\nPR Newswire\n\nNEW YORK, July 30, 2026\n\nImportant Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial\nRisk Misrepresentations. The lawsuit alleges Regeneron investors overpaid\nwhile the Company characterized slowing event accrual as potentially\nfavorable, even as the study allegedly faced heightened risk of failing its\nprimary endpoint.\n\nNEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a class action lawsuit has\nbeen filed on behalf of shareholders who purchased securities between August\n1, 2025 and May 15, 2026. Find out if you could qualify to recover your losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4742050-15&h=3135563518&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195030%26wire%3D4&a=Find+out+if+you+could+qualify+to+recover+your+losses)\n. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nRegeneron shares declined approximately 13.95%, or $102.09 per share, from the\nClass Period high through the final disclosure-related decline. Applications\nto serve as lead plaintiff must be filed by September 14, 2026.\n\nThe Alleged Clinical Trial Risk Securities Fraud Methodology\n\nAccording to the lawsuit, Regeneron provided investors with materially\npositive information about the Phase III Fianlimab-Libtayo Study while\nallegedly mischaracterizing the risk created by a prolonged slowdown in\nprogression-free survival event accrual. The complaint alleges that investors\nwere not told that preliminary statistical assumptions were flawed and that\nthe trial was at increased risk of missing statistical significance.\n\nThe lawsuit contends that the Company framed the slowdown as consistent with\ndurable efficacy in the active treatment arms, rather than as a warning sign\nthat the study's statistical design and endpoint assumptions were under\npressure.\n\nHow Event Accrual Allegedly Affected Investor Expectations\n\nThe Phase III Fianlimab-Libtayo Study tested a LAG-3 inhibitor combination as\na first-line treatment for advanced melanoma. The complaint alleges that\nRegeneron's optimistic discussion of delayed event accrual caused investors to\nform expectations about the program that was not supported by the study's\nactual risk profile.\n\n\"This case presents important questions about clinical-trial risk disclosure\nobligations in the biotechnology sector, particularly where investors are told\nthat delayed events may reflect durable treatment activity. The complaint\nalleges that shareholders were not given a fair picture of the study's\nstatistical risks before the program missed its primary endpoint.\" -- Joseph\nE. Levi, Esq.\n\nKey Clinical Trial Risk Allegations for Shareholders\n\n * The complaint alleges that the slowdown in event accrual was presented as\npotentially favorable to the active treatment arms.\n * The lawsuit contends that the Phase III study's preliminary statistical\nassumptions were materially flawed.\n * Plaintiffs allege that the active treatment arms were not demonstrating the\nclinical separation investors were led to expect.\n * The action claims that the study's risk of failing its primary endpoint was\nunderstated during the Class Period.\n * Regeneron later announced that the trial did not reach statistical\nsignificance for improvement in progression-free survival.\nSubmit your information here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4742050-15&h=3035660308&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195030%26wire%3D4&a=Submit+your+information+here)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REGN Lawsuit\n\nQ: What is the REGN class action lawsuit about? A: A securities class action\nhas been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging\nmaterially false and misleading statements between August 1, 2025 and May 15,\n2026. Shares fell approximately 13.95% after the Company disclosed a protocol\nexpansion for progression-free survival analysis and later announced that the\nPhase 3 Fianlimab trial did not reach statistical significance. Investors who\npurchased shares during the Class Period and suffered losses may be eligible\nto seek compensation.\n\nQ: What specific misstatements does the REGN lawsuit allege? A: The complaint\nalleges Regeneron made materially false or misleading statements regarding the\nPhase III Fianlimab-Libtayo Study, including statements that allegedly\nminimized the clinical and statistical risk associated with slowing event\naccrual. When the protocol change and later trial failure were disclosed, the\nstock price declined sharply.\n\nQ: What court was the REGN class action filed in? A: The case was filed in\nthe United States District Court for the Southern District of New York,\ngoverned by the Private Securities Litigation Reform Act of 1995.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the entire class. Lead\nplaintiffs are typically investors with the largest documented losses. Being\nappointed does not increase individual recovery but gives direct oversight of\nhow the case is run.\n\nQ: What happens after I contact Levi & Korsinsky? A: An attorney will\nreview your trading history at no cost and provide an initial assessment of\nyour potential eligibility.\n\nQ: What if I already sold my REGN shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/regn-deadline-alert-suewallst-reminds-regeneron-pharmaceuticals-regn-investors-of-securities-class-action-deadline-on-september-14-2026-302839146.html\n(https://www.prnewswire.com/news-releases/regn-deadline-alert-suewallst-reminds-regeneron-pharmaceuticals-regn-investors-of-securities-class-action-deadline-on-september-14-2026-302839146.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2803395\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-07-30T15:19:00.108919537Z","server_sent_at_ms":1785424740108},"received_at":"2026-07-30T15:19:00.161Z","source_url":"https://www.prnewswire.com/news-releases/regn-deadline-alert-suewallst-reminds-regeneron-pharmaceuticals-regn-investors-of-securities-class-action-deadline-on-september-14-2026-302839146.html"},"analysis":{"id":"93016","press_release_id":"104002","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky LLP, operating as SueWallSt, issued a solicitation reminder regarding a class action lawsuit against Regeneron Pharmaceuticals.\n\nThe lawsuit alleges Regeneron made misleading statements about the Phase III Fianlimab-Libtayo clinical trial, specifically regarding risk misrepresentations.\n\nThis release is a marketing notice for a lead plaintiff deadline, not an issuer disclosure of new material events.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"}],"products":["Fianlimab","Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN","relationship":"target"},{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$102.09","context":"per share decline from Class Period high"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Levi & Korsinsky/SueWallSt. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"REGN"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky LLP, operating as SueWallSt, issued a solicitation reminder regarding a class action lawsuit against Regeneron Pharmaceuticals.\n\nThe lawsuit alleges Regeneron made misleading statements about the Phase III Fianlimab-Libtayo clinical trial, specifically regarding risk misrepresentations.\n\nThis release is a marketing notice for a lead plaintiff deadline, not an issuer disclosure of new material events.","key_figures":null,"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Attorney"}],"products":["Fianlimab","Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN","relationship":"target"},{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$102.09","context":"per share decline from Class Period high"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-30T20:47:19.925Z","global_importance":15,"audience_relevance":10,"importance_components":{"eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":148128,"modelName":"glm-4.7"}}